Our new Medicine at the Crick event series showcases major advances in biomedical science and raises awareness of the medical implications of major scientific advances amongst the Crick and wider UK biomedical community. Each event comprises a series of short talks, one or two keynote lectures and a panel discussion.

Our third event in the series, Biotherapies in cancer: towards improving clinical outcomes, will review the profound opportunities of CAR-T cell therapy, adoptive cellular immunotherapies and checkpoint inhibitor therapy in the management of haematologic and metastatic solid tumours. These Immunotherapies, by leveraging the patient's immune system, are transforming clinical care, resulting in prolonged survival and even cancer cures in a previously palliative setting. The event will review recent breakthroughs in the field, challenges and opportunities in the translation of scientific findings into the clinic and the promise of leveraging adaptive cellular therapies to tackle cancer clonal evolution for patient benefit.